Latest News

Curious if Union Pacific at around US$238.79 is offering fair value or a margin of safety right now? This article walks through the key numbers that matter for you. The stock has seen mixed returns recently, with a 0.2% move over the last 7 days, a 9.9% decline over 30 days, gains of 3.0% year to date and 3.5% over the last year, and gains of 28.2% over 3 years and 19.6% over 5 years. Recent coverage of Union Pacific has focused on its role as a major U.S. railroad operator and how broader...

Xcel Energy (NasdaqGS:XEL) has filed new regulatory materials with the Federal Energy Regulatory Commission focused on dam safety and compliance. The company’s recent correspondence covers dam stability, embankment integrity, and landslide monitoring at its hydro-related facilities. These filings outline ongoing safety measures and responses to federal oversight of critical infrastructure. Xcel Energy, a regulated electric and natural gas utility, depends on reliable generation and...

For readers wondering whether Smithfield Foods at US$26.69 still offers value, or if the easy gains are already behind it, this article breaks down what the current price might be implying. The stock has returned 13.7% over the past week, 7.3% over the last month, 20.5% year to date, and 36.9% over the past year, which naturally raises questions about how expectations and risk are now being priced in. Recent coverage around Smithfield Foods has focused on its positioning within the food...

China Resources Pharmaceutical Group (SEHK:3320) has come into focus after reporting full year 2025 results and hosting its earnings call, alongside a Board proposal to lift the final cash dividend compared with 2024. See our latest analysis for China Resources Pharmaceutical Group. The earnings release and higher proposed dividend appear to have coincided with a sharp improvement in sentiment, with a 7 day share price return of 28.67% and a 30 day share price return of 25.27% helping lift...

If you are wondering whether Viavi Solutions at US$34.64 is still attractively priced after a big run, the key question is what that price actually reflects about the business. The stock has delivered returns of 3.1% over the past week, 16.6% over the past month, 90.9% year to date and 209.6% over the last year, with a 225.3% return over three years and 114.0% over five years, which puts recent valuation questions front and center. Recent coverage has focused on Viavi Solutions as a...

Hansoh Pharmaceutical Group (SEHK:3692) just posted its FY 2025 first half results with revenue of C¥7.4b and basic EPS of C¥0.53, against a trailing twelve month backdrop of C¥15.0b in revenue and C¥0.93 in EPS off C¥5.6b in net income, as well as earnings growth of 27.1% over the past year. The company has seen revenue move from C¥6.5b and EPS of C¥0.46 in 1H FY 2024 to C¥5.8b and EPS of C¥0.28 in 2H FY 2024, and now to C¥7.4b and EPS of C¥0.53 in 1H FY 2025. This sets up a story where rich...

The Public Service Commission of South Carolina has approved Duke Energy’s plan to build an approximately 1,365 MW high-efficiency natural gas plant in Anderson County, with construction targeted to start in 2027 and operations by early 2031, following an extensive public review and community engagement process. This facility, expected to support more than 2,200 jobs annually during construction and deliver an estimated US$84 million in yearly statewide economic impact once operational, also...

Kindstar Globalgene Technology (SEHK:9960) has reported its FY 2025 first half results with revenue of C¥456.9 million and a basic EPS loss of C¥0.0378, while trailing 12 month figures show revenue of C¥933.6 million and a basic EPS loss of C¥0.0592. Over the past three half year periods, revenue has moved from C¥473.3 million in 1H 2024 to C¥454.2 million in 2H 2024 and C¥456.9 million in 1H 2025, alongside a shift in basic EPS from C¥0.0125 to a loss of C¥0.0706 and then a smaller loss of...

Palvella Therapeutics (NasdaqCM:PVLA) has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services. McDonough has extensive experience launching and commercializing therapies for rare skin diseases, including work on VYJUVEK®. The appointment is intended to support Palvella’s commercial readiness as QTORIN™ rapamycin advances through late-stage trials. For investors watching rare disease drug developers, Palvella Therapeutics sits at the intersection of...

In the past week, Best Buy reported quarterly results showing adjusted EPS of US$2.61, up 1.2% year over year, alongside a 0.8% decline in comparable sales and slightly softer-than-expected revenue, while also announcing a 1% increase in its quarterly dividend to US$0.96 per share. Management’s decision to raise the dividend and emphasize scalable profit drivers such as its digital Marketplace and Best Buy Ads highlights a focus on recurring, higher-margin revenue streams even as top-line...

In late March 2026, Paychex reported third-quarter revenue of US$1,808.9 million and net income of US$560.3 million, alongside updates on completing two share repurchase authorizations totaling US$400 million and US$352.22 million, and highlighted its cybersecurity focus ahead of an RSA Conference presentation. While revenue and quarterly earnings per share increased year over year, nine-month net income and EPS were slightly lower, underscoring that growth in sales has not yet translated...

Investors may be wondering whether Subsea 7's strong share price run has already priced in the opportunity, or if there could still be value on the table. The stock last closed at NOK 281.40, with returns of 6.7% over 7 days, 2.4% over 30 days, 35.3% year to date and 80.7% over 1 year. This naturally raises questions about how those moves line up with underlying value. Recent attention on Subsea 7 has centered on its role in energy services and investor interest in offshore projects, which...

If you are wondering whether Cal-Maine Foods at around US$77.12 is pricing in too much optimism or leaving some value on the table, a closer look at its valuation can help frame that question. The share price is near US$77.12 after a 0.1% move over the last 7 days, with an 11.5% decline over 30 days, a 1.7% decline year to date, a 7.8% decline over 1 year, but a 53.8% gain over 3 years and a 159.0% gain over 5 years. Recent coverage has focused on Cal-Maine Foods as a key player in the US...

CDW stock performance context CDW (CDW) has drawn attention after a period where the share price shows a 2.5% decline over the past day and negative returns over the week, month, past 3 months, year to date, and past year. See our latest analysis for CDW. At a share price of $118.17, CDW’s recent 1 day share price decline of 2.5% sits within a broader period of weaker momentum, with a 1 year total shareholder return of 25.0% in the red. This may reflect cooler sentiment around its risk and...

If you are wondering whether lululemon athletica's current share price really reflects what the business is worth, starting with a clear look at valuation can help you frame that question properly. The stock last closed at US$145.85, with returns of an 11.3% decline over 7 days, a 21.2% decline over 30 days, a 30.8% decline year to date, and a 48.5% decline over the past year, which has likely shifted how many investors think about its potential and risk. Recent headlines around lululemon...

As the London markets grapple with global economic uncertainties, particularly the ripple effects of China's sluggish recovery, investors are increasingly looking for opportunities beyond the traditional blue-chip stocks. Penny stocks, though a somewhat outdated term, still represent a compelling investment area for those seeking growth potential in smaller or newer companies. When these stocks are supported by strong financials and solid fundamentals, they can offer unique opportunities for...

For readers wondering whether Indivior Pharmaceuticals at around US$28.97 is still a good entry point or more of a hold after such a big run, this article focuses squarely on what the current valuation is indicating. The stock has pulled back, with a 1.4% decline over the last 7 days, an 11.5% decline over 30 days, and an 18.9% decline year to date. This follows a very strong 204.0% return over 1 year and 216.6% over 5 years. Recent attention around Indivior Pharmaceuticals has centered on...

Over the past year, Agnico Eagle Mines has seen substantial insider selling, including about US$16,000,000 of stock offloaded in the last quarter with no corresponding insider purchases, and the largest single sale coming from CEO Ammar Al-Joundi at a price below where the shares trade today. This pattern of executives reducing their holdings without any offsetting buys may raise questions for investors about how insiders currently view the company’s valuation. Next, we’ll examine how this...

Alvopetro Energy Ltd.'s ( CVE:ALV ) stock was strong after they recently reported robust earnings. However, we think...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Morningstar...

Fosun International share performance snapshot Fosun International (SEHK:656) has drawn investor attention after recent share price moves, with the stock showing a 2.2% decline over the past day but gains over the past week and month. See our latest analysis for Fosun International. That 2.2% one-day share price decline comes after a 9.5% seven-day share price return and a weaker one-year total shareholder return of a 2.7% decline, which suggests recent momentum contrasts with longer-term...

Electronic Arts (NasdaqGS:EA) has completed a multi billion dollar private equity takeover, reshaping its ownership structure. JPMorgan Chase & Co. arranged complex financing to close the leveraged buyout in challenging market conditions. Management is highlighting plans to use artificial intelligence to drive the next phase of the company’s growth focus. For investors watching NasdaqGS:EA, the completed deal comes with the stock at $202.01 and a 1 year return of 40.4%. Over 3 years, the...

Cardinal Health recently announced that Patricia A. Hemingway Hall has succeeded Gregory B. Kenny as Chair of the Board following his retirement on March 23, 2026, after his long tenure guiding the company through portfolio changes and operational improvement efforts. Hemingway Hall’s elevation to Chair brings the perspective of a former health insurer CEO and long-serving governance leader at Cardinal Health, potentially shaping how the company approaches healthcare partnerships and...

What stands out about Stock Yards Bancorp right now Stock Yards Bancorp (SYBT) has drawn attention after recent trading left the shares around $63.91, with returns showing small single digit moves over the past week, month, and past 3 months. See our latest analysis for Stock Yards Bancorp. While the 1 day share price return of 2.31% and year to date share price return of 1.98% are both negative, the 3 year total shareholder return of 24.86% and 5 year total shareholder return of 37.15%...